Cargando…
Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study
BACKGROUND: Human telomerase reverse transcriptase (hTERT) is an antigen that may represent a target for a novel anti-cancer strategy. A pilot, phase I study tested the safety and feasibility of a prime-boost immunization regimen based on V935, an adenoviral type 6 vector vaccine expressing a modifi...
Autores principales: | Aurisicchio, Luigi, Fridman, Arthur, Mauro, David, Sheloditna, Rose, Chiappori, Alberto, Bagchi, Ansuman, Ciliberto, Gennaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993365/ https://www.ncbi.nlm.nih.gov/pubmed/32000810 http://dx.doi.org/10.1186/s12967-020-02228-9 |
Ejemplares similares
-
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
por: Diaz, Claudia Marcela, et al.
Publicado: (2013) -
A novel minigene scaffold for therapeutic cancer vaccines
por: Aurisicchio, Luigi, et al.
Publicado: (2014) -
An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform
por: Fridman, Arthur, et al.
Publicado: (2012) -
A Novel Long Non-Coding RNA in the hTERT Promoter Region Regulates hTERT Expression
por: Malhotra, Sanandan, et al.
Publicado: (2017) -
An Improved Model for the hTERT Promoter Quadruplex
por: Chaires, Jonathan B., et al.
Publicado: (2014)